Drug Database
Back to search

Poland· PL-100389762

Lamivudine + Zidovudine Accord

A zidovudine and lamivudine product containing lamivudinum + zidovudinum, registered in Poland by Accord Healthcare Polska Sp. z o.o.. The same ATC class is registered in 14 of our 19 countries.

ATC J05AR01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedLamivudine + Zidovudine AccordATCJ05AR01REGISTER NO.PL-100389762PACKS LISTED5CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lamivudinum + zidovudinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Zidovudine and lamivudine is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AR01 (zidovudine and lamivudine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search zidovudine and lamivudine products by name

Zidovudine and lamivudine · ATC J05AR01

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Lamivudinum + Zidovudinum
Manufacturer
Accord Healthcare Polska Sp. z o.o.
Country
Poland (PL)
ATC code
J05AR01
ATC class
Zidovudine and lamivudine
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 5

  • gtin
    05909991370435
  • gtin
    05909991370442
  • gtin
    05909991370459
  • gtin
    05909991370466
  • gtin
    05909991370473

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for zidovudine and lamivudine.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check zidovudine and lamivudine against other medicinesHow interaction checks work

Zidovudine and lamivudine · interactions on record

1 record

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Zidovudine and lamivudine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All zidovudine and lamivudine products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Belgium · Lamivudine/Zidovudine Viatris
  • Cyprus · Lamivudine/Zidovudine Aurobindo
  • Germany · Lamivudin/Zidovudin, Lamivudin/Zidovudin Accord
  • France · Lamivudine/Zidovudine Arrow, Lamivudine/Zidovudine Viatris
  • United Kingdom (Northern Ireland) · Lamivudine/Zidovudine Milpharm, Lamivudine/Zidovudine Mylan
  • Iceland · Combivir
  • Italy · Lamivudina E Zidovudina Aurobindo, Lamivudina E Zidovudina Mylan
  • Liechtenstein · Combivir
  • Luxembourg · Lamivudine/Zidovudine Viatris
  • Malta · Lamivudine/Zidovudine Mylan
  • Netherlands · Lamivudine/Zidovudine Aurobindo, Lamivudine/Zidovudine Viatris
  • Norway · Combivir
  • Portugal · Lamivudina + Zidovudina Accord, Lamivudina + Zidovudina Aurobindo
  • Romania · Lamivudină/Zidovudină Aurobindo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bfe792f1-dab1-494d-8b19-a2a4407cb43c
GET /v1/drugs/bfe792f1-dab1-494d-8b19-a2a4407cb43c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "150 mg + 300 mg",
  "packaging": "05909991370435 ¦ Rp ¦ 127884\n60 tabl. w butelce\n05909991370442 ¦ Rp ¦ 127885\n60 tabl. w blistrze\n05909991370459 ¦ Rp ¦ 127886\n120 tabl.\n05909991370466 ¦ Rp ¦ 127887\n200 tabl.\n05909991370473 ¦ Rp ¦ 127888\n500 tabl.",
  "substance": "Lamivudinum 150 mg + Zidovudinum 300 mg",
  "common_name": "Lamivudinum + Zidovudinum",
  "pl_product_id": "100389762",
  "pozwolenie_nr": "24703",
  "auth_procedure": "MRP",
  "authorisation_validity": "2023-12-08"
}
API referenceMCP serverPlans

See everything about zidovudine and lamivudine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console